Clinical and Demographic Characteristics of Adult p atients with NEurofibromatosis in RUSsia

Trial Identifier:	D134BR00007
Sponsor:	AstraZeneca
Start Date:	June 2025
Primary Completion Date:	March 2028
Study Completion Date:	March 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russia	Moscow, Russia

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.